Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Molecular and Cellular Mechanism in Rhinitis Allergic Patients Treated With GRAZAX®

NCT02437786 is registered in ClinicalTrials.gov with ALK-Abelló A/S as lead sponsor.

NCT NCT02437786
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02437786 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Molecular and Cellular Mechanism in Rhinitis Allergic Patients Treated With GRAZAX®
Lead sponsor
ALK-Abelló A/S
Phase
Phase 4
Overall status
Completed
Start date
September 30, 2009
Completion date
December 31, 2014
Enrollment
58 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

allergic rhinoconjunctivitis